A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.
Key Eligibility Criteria:
FURMO006CT@arrivent.com(888) 622-2827
Sacramento, California 95817, United States
Chicago, Illinois 60612, United States
New York, New York 10016, United States
Toronto, Ontario M5G 2M9, Canada
Athens, 124 62, Greece
Thessaloniki, 570 01, Greece
Kurume-Shi, Fukuoka 830-0011, Japan
Akashi-shi, Hyōgo 673-8558, Japan
Hirakata-shi, Osaka 573-1191, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Bunkyō-Ku, Tokyo 113-8677, Japan
Chuo-ku, Tokyo 104-0045, Japan
Suwon, Gyeonggi-do 16247, South Korea
Bangkoknoi, Bangkok 10700, Thailand
London, England NW1 2PG, United Kingdom